Protara Updates TARA-002 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Protara Therapeutics announced updated 12-month data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS non-muscle invasive bladder cancer. These results in Bacillus Calmette-Guerin-Naive NMIBC patients will be featured today during a poster session at the American Urological Association annual meeting in Washington, D.C. The BCG-Naive dataset includes a total of 31 patients of whom 29 were evaluable for efficacy, with 27 patients evaluable at six months and 20 patients evaluable at 12 months, as of an April 5 data cutoff. The CR rate at any time in BCG-Naive patients was 72.4%. The CR rate in BCG-Naive patients was 66.7% at six months and 55% at 12 months. The Kaplan-Meier estimated probability of maintaining a CR for six months was 73.1%. Overall, 91.7% maintained their CR from nine to 12 months. Overall, 66.7% of re-induced patients converted to a CR at six months. The majority of treatment-related adverse events were Grade 1 and transient, with no Grade 3 or greater TRAEs reported, as assessed by study investigators. No patients discontinued treatment due to TRAEs. The most commonly reported TRAEs were dysuria, fatigue, and hematuria.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TARA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TARA
Wall Street analysts forecast TARA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.750
Low
23.00
Averages
25.50
High
30.00
Current: 4.750
Low
23.00
Averages
25.50
High
30.00
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Protara Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Protara Therapeutics reported a Q1 GAAP EPS of -$0.31, beating expectations by $0.06, indicating improvements in financial management and increased market confidence.
- Strong Cash Position: As of March 31, 2026, the company had $177.4 million in unrestricted cash and cash equivalents, which is expected to fund operations and milestones through 2028, bolstering investor confidence in its long-term growth.
- Clinical Progress Update: Protara presented interim Phase II results for TARA-002 in non-muscle invasive bladder cancer at the 2026 ASCO Genitourinary Cancers Symposium, further validating the potential of its product pipeline and laying the groundwork for future market performance.
- Increased Market Attention: JP Morgan initiated coverage on Protara with an “overweight” rating, reflecting recognition of its future growth potential, which may attract more investor interest in the company.
See More
Protara Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Protara Therapeutics reported a Q4 2025 GAAP EPS of -$0.37, indicating challenges in profitability that may impact investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $197.9 million in unrestricted cash and cash equivalents, including $86.3 million from its public offering, providing a solid financial foundation for future operations.
- Funding Outlook: The company expects its cash and cash equivalents will be sufficient to fund planned operations and milestones through 2028, reflecting strong financial management and strategic planning.
- Market Reaction: Despite presenting interim Phase II results for TARA-002 at the ASCO 2026 Genitourinary Cancers Symposium, the market's mixed response to mid-stage trial data for its lead asset has led to stock price volatility.
See More
JP Morgan Initiates Protara with Overweight Rating
- Stock Surge: Protara Therapeutics (TARA) rose approximately 5% in premarket trading on Wednesday, reflecting a positive market reaction to JP Morgan's overweight rating, indicating investor confidence in the company's growth potential.
- Price Target Set: JP Morgan's price target of $27 implies a ~339% upside based on the March 3 closing price, suggesting analysts' optimistic outlook on Protara's prospects, which may attract more investor interest.
- Core Product Advantage: Analyst Brian Cheng highlighted that Protara's main candidate, TARA-002, is a cell therapy in phase 2 for non-muscle invasive bladder cancer, with clinical experience significantly de-risking it, enhancing its competitive position in the market.
- Market Positioning Outlook: Cheng noted that TARA-002's ease of use positions it as BCG 2.0, expected to gain significant adoption among high-risk BCG-naive non-muscle invasive bladder cancer patients, further driving the company's market share in the biotech sector.
See More
Latest Ratings and Price Targets on Wall Street
- nLIGHT Coverage Initiation: Baird initiates coverage of nLIGHT with an Outperform rating and a $95 price target, citing favorable market trends and robust funding that support growth, particularly enhanced by the company's vertical integration and technological strengths.
- Apple's New Product Launch: Oppenheimer reiterates Apple as Perform, highlighting the new MacBook Pro lines powered by M5 Pro and M5 Max chips, which signify a new era of local AI computing and reinforce Apple's significant lead in efficiency and scalability in personal computing devices.
- PulteGroup and Toll Brothers Ratings: Truist initiates PulteGroup and Toll Brothers with Buy ratings, setting a price target of $170, as they believe the market is significantly undervaluing both companies' profitability potential, especially in the context of a recovering luxury housing market.
- Tesla and General Motors Upgrades: Bank of America upgrades Tesla to Buy with a $460 price target, viewing it as the leader in consumer autonomy, while reinstating General Motors as Buy, expecting benefits from lower warranty costs and regulatory credits.
See More
Protara Therapeutics Reports Interim Data for TARA-002 in Bladder Cancer Trial
- Clinical Trial Update: Protara Therapeutics reported a 68.2% complete response rate for TARA-002 in its mid-stage trial for non-muscle invasive bladder cancer, leading to a ~22% drop in stock price due to mixed results.
- BCG Response Rates: In the BCG-unresponsive cohort, complete response rates were 68.2% at six months and 33.3% at twelve months, while BCG-naïve patients showed rates of 66.7% and 57.9%, indicating variability in treatment effectiveness.
- Safety Profile: The cell-based therapy maintained a favorable safety and tolerability profile, with no Grade 3 or higher treatment-related adverse events reported, suggesting a lower risk for patients undergoing treatment.
- Future Plans: Protara reaffirmed plans to initiate the ADVANCED-3 registrational trial for BCG-naïve patients in H2 2026, with enrollment in the BCG-unresponsive cohort expected to conclude later this year, demonstrating the company's ongoing commitment to future growth.
See More
Protara Therapeutics Updates TARA-002 Trial Results
- Clinical Trial Response Rate: The ADVANCED-2 trial revealed a 68.2% complete response rate at six months for the BCG-Unresponsive cohort treated with TARA-002, indicating significant therapeutic potential without any Grade 3 or higher treatment-related adverse events reported.
- Response Maintenance Probability: Among responders, the Kaplan-Meier estimated probability of maintaining a complete response for six months was 71.1%, with 100% of patients maintaining their complete response from nine to twelve months, highlighting the drug's promising long-term efficacy.
- BCG Naïve Patient Performance: In the BCG-naïve cohort of 27 patients, the complete response rate was 72.4% at any time and 66.7% at six months, further validating TARA-002's effectiveness across different patient populations and potentially offering new treatment avenues.
- Market Performance Analysis: Protara shares fell 7.94% to $6.84 in premarket trading, trading 12.65% below its 20-day simple moving average, indicating a bearish short-term trend, which suggests that investors should exercise caution.
See More
Protara Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Protara Therapeutics reported a Q1 GAAP EPS of -$0.31, beating expectations by $0.06, indicating improvements in financial management and increased market confidence.
- Strong Cash Position: As of March 31, 2026, the company had $177.4 million in unrestricted cash and cash equivalents, which is expected to fund operations and milestones through 2028, bolstering investor confidence in its long-term growth.
- Clinical Progress Update: Protara presented interim Phase II results for TARA-002 in non-muscle invasive bladder cancer at the 2026 ASCO Genitourinary Cancers Symposium, further validating the potential of its product pipeline and laying the groundwork for future market performance.
- Increased Market Attention: JP Morgan initiated coverage on Protara with an “overweight” rating, reflecting recognition of its future growth potential, which may attract more investor interest in the company.
See More
Protara Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Protara Therapeutics reported a Q4 2025 GAAP EPS of -$0.37, indicating challenges in profitability that may impact investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $197.9 million in unrestricted cash and cash equivalents, including $86.3 million from its public offering, providing a solid financial foundation for future operations.
- Funding Outlook: The company expects its cash and cash equivalents will be sufficient to fund planned operations and milestones through 2028, reflecting strong financial management and strategic planning.
- Market Reaction: Despite presenting interim Phase II results for TARA-002 at the ASCO 2026 Genitourinary Cancers Symposium, the market's mixed response to mid-stage trial data for its lead asset has led to stock price volatility.
See More
JP Morgan Initiates Protara with Overweight Rating
- Stock Surge: Protara Therapeutics (TARA) rose approximately 5% in premarket trading on Wednesday, reflecting a positive market reaction to JP Morgan's overweight rating, indicating investor confidence in the company's growth potential.
- Price Target Set: JP Morgan's price target of $27 implies a ~339% upside based on the March 3 closing price, suggesting analysts' optimistic outlook on Protara's prospects, which may attract more investor interest.
- Core Product Advantage: Analyst Brian Cheng highlighted that Protara's main candidate, TARA-002, is a cell therapy in phase 2 for non-muscle invasive bladder cancer, with clinical experience significantly de-risking it, enhancing its competitive position in the market.
- Market Positioning Outlook: Cheng noted that TARA-002's ease of use positions it as BCG 2.0, expected to gain significant adoption among high-risk BCG-naive non-muscle invasive bladder cancer patients, further driving the company's market share in the biotech sector.
See More
Latest Ratings and Price Targets on Wall Street
- nLIGHT Coverage Initiation: Baird initiates coverage of nLIGHT with an Outperform rating and a $95 price target, citing favorable market trends and robust funding that support growth, particularly enhanced by the company's vertical integration and technological strengths.
- Apple's New Product Launch: Oppenheimer reiterates Apple as Perform, highlighting the new MacBook Pro lines powered by M5 Pro and M5 Max chips, which signify a new era of local AI computing and reinforce Apple's significant lead in efficiency and scalability in personal computing devices.
- PulteGroup and Toll Brothers Ratings: Truist initiates PulteGroup and Toll Brothers with Buy ratings, setting a price target of $170, as they believe the market is significantly undervaluing both companies' profitability potential, especially in the context of a recovering luxury housing market.
- Tesla and General Motors Upgrades: Bank of America upgrades Tesla to Buy with a $460 price target, viewing it as the leader in consumer autonomy, while reinstating General Motors as Buy, expecting benefits from lower warranty costs and regulatory credits.
See More
Protara Therapeutics Reports Interim Data for TARA-002 in Bladder Cancer Trial
- Clinical Trial Update: Protara Therapeutics reported a 68.2% complete response rate for TARA-002 in its mid-stage trial for non-muscle invasive bladder cancer, leading to a ~22% drop in stock price due to mixed results.
- BCG Response Rates: In the BCG-unresponsive cohort, complete response rates were 68.2% at six months and 33.3% at twelve months, while BCG-naïve patients showed rates of 66.7% and 57.9%, indicating variability in treatment effectiveness.
- Safety Profile: The cell-based therapy maintained a favorable safety and tolerability profile, with no Grade 3 or higher treatment-related adverse events reported, suggesting a lower risk for patients undergoing treatment.
- Future Plans: Protara reaffirmed plans to initiate the ADVANCED-3 registrational trial for BCG-naïve patients in H2 2026, with enrollment in the BCG-unresponsive cohort expected to conclude later this year, demonstrating the company's ongoing commitment to future growth.
See More
Protara Therapeutics Updates TARA-002 Trial Results
- Clinical Trial Response Rate: The ADVANCED-2 trial revealed a 68.2% complete response rate at six months for the BCG-Unresponsive cohort treated with TARA-002, indicating significant therapeutic potential without any Grade 3 or higher treatment-related adverse events reported.
- Response Maintenance Probability: Among responders, the Kaplan-Meier estimated probability of maintaining a complete response for six months was 71.1%, with 100% of patients maintaining their complete response from nine to twelve months, highlighting the drug's promising long-term efficacy.
- BCG Naïve Patient Performance: In the BCG-naïve cohort of 27 patients, the complete response rate was 72.4% at any time and 66.7% at six months, further validating TARA-002's effectiveness across different patient populations and potentially offering new treatment avenues.
- Market Performance Analysis: Protara shares fell 7.94% to $6.84 in premarket trading, trading 12.65% below its 20-day simple moving average, indicating a bearish short-term trend, which suggests that investors should exercise caution.
See More
